BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 33336265)

  • 1. Prognostic implications of dual tracer PET/CT: PSMA ligand and [
    Michalski K; Ruf J; Goetz C; Seitz AK; Buck AK; Lapa C; Hartrampf PE
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2024-2030. PubMed ID: 33336265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response assessment using
    Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [
    Hartrampf PE; Lapa C; Serfling SE; Buck AK; Seitz AK; Meyer PT; Ruf J; Michalski K
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy, prognostic variables and clinical outcome of
    Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
    Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
    Karimzadeh A; Heck M; Tauber R; Solaris E; Nekolla S; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I
    J Nucl Med; 2023 Aug; 64(8):1252-1258. PubMed ID: 37290796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with
    Murthy V; Gafita A; Thin P; Nguyen K; Grogan T; Shen J; Drakaki A; Rettig M; Czernin J; Calais J
    J Nucl Med; 2023 Nov; 64(11):1737-1743. PubMed ID: 37678927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy.
    Michalski K; Kosmala A; Werner RA; Serfling SE; Seitz AK; Lapa C; Buck AK; Hartrampf PE
    Ann Nucl Med; 2024 Feb; 38(2):87-95. PubMed ID: 37891376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prognostic Value of Posttreatment
    Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
    J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with
    Telli T; Tuncel M; Karabulut E; Aksoy S; Erman M; Akdogan B; Caglar M
    Prostate; 2023 Jun; 83(8):792-800. PubMed ID: 36919876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early molecular imaging response assessment based on determination of total viable tumor burden in [
    Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Performance of RECIP 1.0 Based on [
    Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Higuchi T; Schlötelburg W; Michalski K; Gafita A; Rowe SP; Pomper MG; Buck AK; Werner RA
    J Nucl Med; 2024 Apr; 65(4):560-565. PubMed ID: 38453363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
    Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC.
    Laarhuis BI; Janssen MJR; Simons M; van Kalmthout LWM; van der Doelen MJ; Peters SMB; Westdorp H; van Oort IM; Litjens G; Gotthardt M; Nagarajah J; Mehra N; Privé BM
    Clin Genitourin Cancer; 2023 Oct; 21(5):e352-e361. PubMed ID: 37164814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
    Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
    Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Tumor Volume Assessment on PSMA PET After
    Kind F; Eder AC; Jilg CA; Hartrampf PE; Meyer PT; Ruf J; Michalski K
    J Nucl Med; 2023 Apr; 64(4):605-610. PubMed ID: 36302658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy.
    Widjaja L; Werner RA; Krischke E; Christiansen H; Bengel FM; Bogdanova N; Derlin T
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):602-612. PubMed ID: 36136101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
    Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
    Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer.
    Soydal C; Araz M; Urun Y; Nak D; Ozkan E; Kucuk NO
    Q J Nucl Med Mol Imaging; 2021 Sep; 65(3):282-286. PubMed ID: 31602963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of Combined PET Imaging with [
    Khreish F; Ribbat K; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Schreckenberger M; Ezziddin S; Rosar F
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
    J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.